Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy Plus Trastuzumab With Lapatinib in Resected HER2+ Breast Cancer
NCT00436566Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2007
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lapatinib in breast cancer (2 arms), sponsored by Mayo Clinic. Primary endpoint: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment at 6 months. Started Mar 2007; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00436566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436566.